ArticleJournal of the National Comprehensive Cancer Network : JNCCN2025

Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.

Sarah Waliany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.